Advertisement

Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma

      Objective

      To evaluate postoperative recurrence patterns for high-risk nonmetastatic renal cell carcinoma (RCC) and to identify prognostic factors associated with site-specific metastatic recurrence using a multi-institutional contemporary cohort.

      Methods

      Data for nonmetastatic ≥pT3a RCC patients treated with surgery at 4 independent centers was analyzed. Initial recurrence locations were identified, and imaging templates were defined by anatomic landmarks using radiologic definitions. Prognostic factors for site specific recurrence were evaluated with univariate and multivariable analyses.

      Results

      A total of 1057 patients were treated surgically for ≥pT3a RCC. Initial recurrence location was in a single site for 160 (59.3%) patients and at multiple locations in 110 (41.7%) patients. The most common sites of metastatic recurrence were lung (144/270, 53.3%), liver (54/270, 20.0%), and bone (48/270, 17.8%).
      Recurrence was identified in 52 of 270 (19.3%) patients outside the chest/abdomen template, most commonly in the pelvis (25/270, 9.3%). Bone and brain metastases were the most common organs for metastases outside chest/abdomen. Patients with tumor diameter >10 cm and grade 4 were more likely to recur in the bone (HR 3.61, P <.001) and brain (HR 16.5, P <.001).

      Conclusion

      Metastatic progression outside chest/abdomen imaging templates was present in 1 of 5 high risk patients at initial metastatic RCC diagnosis, most commonly in the pelvis. Patients with large (>10 cm) tumors and grade 4 histology are at highest risk for bone and brain metastases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ravaud A
        • Motzer RJ
        • Pandha HS
        • et al.
        Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.
        N Engl J Med. 2016; 375: 2246-2254
        • Haas NB
        • Manola J
        • Uzzo RG
        • et al.
        Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
        Lancet. 2016; 387: 2008-2016
        • Bianchi M
        • Sun M
        • Jeldres C
        • et al.
        Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.
        Ann Oncol. 2012; 23: 973-980
        • Griffin N
        • Gore ME
        • Sohaib SA
        Imaging in metastatic renal cell carcinoma.
        AJR Am J Roentgenol. 2007; 189: 360-370
        • Stewart-Merrill SB
        • Thompson RH
        • Boorjian SA
        • et al.
        Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach.
        J Clin Oncol. 2015; 33: 4151-4157
        • Donat SM
        • Diaz M
        • Bishoff JT
        • et al.
        Follow-up for clinically localized renal neoplasms: AUA guideline.
        J Urol. 2013; 190: 407-416
        • Motzer RJ
        • Jonasch E
        • Agarwal N
        • et al.
        Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2017; 15: 804-834
        • Ljungberg B
        • Albiges L
        • Abu-Ghanem Y
        • et al.
        European association of urology guidelines on renal cell carcinoma: the 2019 update.
        Eur Urol. 2019; 75: 799-810
        • Leibovich BC
        • Blute ML
        • Cheville JC
        • et al.
        Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
        Cancer. 2003; 97: 1663-1671
        • Zisman A
        • Pantuck AJ
        • Wieder J
        • et al.
        Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.
        J Clin Oncol. 2002; 20: 4559-4566
        • Stewart SB
        • Thompson RH
        • Psutka SP
        • et al.
        Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.
        J Clin Oncol. 2014; 32: 4059-4065
        • Grunwald V
        • Eberhardt B
        • Bex A
        • et al.
        An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.
        Nat Rev Urol. 2018; 15: 511-521
        • Guida A
        • Escudier B
        • Albiges L
        Treating patients with renal cell carcinoma and bone metastases.
        Expert Rev Anticancer Ther. 2018; 18: 1135-1143
        • Santini D
        • Procopio G
        • Porta C
        • et al.
        Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
        PLoS One. 2013; 8: e83026
        • Gerety EL
        • Lawrence EM
        • Wason J
        • et al.
        Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
        Ann Oncol. 2015; 26: 2113-2118
        • Wang X
        • Pirasteh A
        • Brugarolas J
        • et al.
        Whole-body MRI for metastatic cancer detection using T.
        Magn Reson Med. 2018; 80: 1402-1415
        • Vickers MM
        • Al-Harbi H
        • Choueiri TK
        • et al.
        Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
        Clin Genitourin Cancer. 2013; 11: 311-315
        • Suarez-Sarmiento Jr., A
        • Nguyen KA
        • Syed JS
        • et al.
        Brain metastasis from renal-cell carcinoma: an institutional study.
        Clin Genitourin Cancer. 2019; 17: e1163-e1170
        • Bowman IA
        • Bent A
        • Le T
        • et al.
        Improved survival outcomes for kidney cancer patients with brain metastases.
        Clin Genitourin Cancer. 2019; 17: e263-e272
        • Gulati S
        • Vaishampayan U
        Current state of systemic therapies for advanced renal cell carcinoma.
        Curr Oncol Rep. 2020; 22: 26
        • Motzer RJ
        • Tannir NM
        • McDermott DF
        • et al.
        Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378: 1277-1290